PetIQ Inc (NASDAQ:PETQ) CFO John Newland sold 5,500 shares of the firm’s stock in a transaction that occurred on Monday, August 13th. The stock was sold at an average price of $26.78, for a total transaction of $147,290.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

John Newland also recently made the following trade(s):

  • On Tuesday, July 17th, John Newland sold 5,500 shares of PetIQ stock. The stock was sold at an average price of $26.03, for a total transaction of $143,165.00.
  • On Wednesday, June 27th, John Newland sold 11,000 shares of PetIQ stock. The stock was sold at an average price of $25.25, for a total transaction of $277,750.00.
  • On Thursday, June 21st, John Newland sold 5,500 shares of PetIQ stock. The stock was sold at an average price of $24.53, for a total transaction of $134,915.00.

Shares of PetIQ stock opened at $34.25 on Friday. The firm has a market cap of $665.34 million and a PE ratio of 87.82. PetIQ Inc has a 1-year low of $17.03 and a 1-year high of $37.45. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.09 and a current ratio of 2.35.

PetIQ (NASDAQ:PETQ) last issued its quarterly earnings results on Tuesday, August 14th. The company reported $0.41 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.39 by $0.02. The business had revenue of $171.10 million for the quarter, compared to analysts’ expectations of $148.48 million. PetIQ had a net margin of 0.17% and a return on equity of 11.39%. The business’s quarterly revenue was up 96.2% compared to the same quarter last year. equities analysts expect that PetIQ Inc will post 0.78 EPS for the current fiscal year.

Several equities research analysts recently issued reports on PETQ shares. BidaskClub cut shares of PetIQ from a “hold” rating to a “sell” rating in a report on Friday, May 4th. Jefferies Financial Group restated a “buy” rating and issued a $30.00 target price on shares of PetIQ in a report on Wednesday, May 16th. Zacks Investment Research cut shares of PetIQ from a “hold” rating to a “sell” rating in a report on Wednesday, May 16th. ValuEngine upgraded shares of PetIQ from a “hold” rating to a “buy” rating in a report on Thursday, July 12th. Finally, SunTrust Banks raised their target price on shares of PetIQ to $40.00 and gave the stock a “buy” rating in a report on Wednesday. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. PetIQ currently has a consensus rating of “Buy” and a consensus price target of $33.33.

Several institutional investors have recently modified their holdings of the company. Millennium Management LLC boosted its stake in shares of PetIQ by 17.4% during the 2nd quarter. Millennium Management LLC now owns 75,172 shares of the company’s stock worth $2,019,000 after acquiring an additional 11,150 shares during the last quarter. Waddell & Reed Financial Inc. boosted its stake in shares of PetIQ by 5.1% during the 2nd quarter. Waddell & Reed Financial Inc. now owns 216,100 shares of the company’s stock worth $5,804,000 after acquiring an additional 10,500 shares during the last quarter. Portolan Capital Management LLC boosted its stake in shares of PetIQ by 53.0% during the 2nd quarter. Portolan Capital Management LLC now owns 202,592 shares of the company’s stock worth $5,442,000 after acquiring an additional 70,149 shares during the last quarter. Raymond James & Associates boosted its stake in shares of PetIQ by 194.4% during the 2nd quarter. Raymond James & Associates now owns 130,834 shares of the company’s stock worth $3,514,000 after acquiring an additional 86,400 shares during the last quarter. Finally, Gamco Investors INC. ET AL purchased a new position in shares of PetIQ during the 2nd quarter worth $806,000. Institutional investors and hedge funds own 79.77% of the company’s stock.

About PetIQ

PetIQ, Inc develops, manufactures, and distributes pet medications, and health and wellness products for dogs and cats in the United States, Canada, and Europe. It offers pet prescription medications, including products for arthritis, thyroid, and diabetes and pain treatments, as well as heartworm preventatives, antibiotics, and other specialty medications; over-the-counter medications and supplies, such as flea and tick control products in various forms comprising spot on treatments, chewables, and collars; and health and wellness products consisting of specialty treats and other pet products, which include dental treats and nutritional supplements.

Featured Story: Stock Symbols and CUSIP Explained

Insider Buying and Selling by Quarter for PetIQ (NASDAQ:PETQ)

Receive News & Ratings for PetIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ and related companies with MarketBeat.com's FREE daily email newsletter.